首页 > 最新文献

Minerva obstetrics and gynecology最新文献

英文 中文
Pathophysiology and diagnostic criteria of PCOS. 多囊卵巢综合征的病理生理及诊断标准。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 Epub Date: 2025-01-30 DOI: 10.23736/S2724-606X.24.05612-4
Anna Capozzi, Michele Vignali, Giovanni Scambia, Stefano Lello

Introduction: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic syndrome mainly characterized by ovarian dysfunction, which is only one manifestation of a more complex syndrome with a significant systemic impact.

Evidence acquisition: We review scientific literature on the pathophysiology and diagnosis of PCOS evaluating the most relevant data from original articles, reviews and meta-analyses published until June 2024.

Evidence synthesis: From a pathophysiological point of view, the concurrence of both metabolic aspects, such as insulin resistance and obesity, and hormonal alterations, such as hyperandrogenemia, might produce the most relevant clinical signs and/symptoms of this syndrome, for instance menstrual irregularities, hair loss, acne and hirsutism. In the latest years, many pieces of evidence highlighted the importance of family history and genetics in the development of the syndrome during adolescence and adult life. According to the available data, hypovitaminosis D could play a detrimental role in the pathogenesis and clinical manifestations of PCOS.

Conclusions: PCOS is a challenging endocrine and metabolic dysfunction, due to its different expression among women and to the difficulty in obtaining an accurate diagnosis. The most appropriate approach to women affected by PCOS should involve a multi-step strategy, taking into account the characteristics of each patient, in order to identify the best non-pharmacologic and pharmacologic approach to manage both short- and medium-, and long-term sequelae.

简介:多囊卵巢综合征(Polycystic ovarian syndrome, PCOS)是一种以卵巢功能障碍为主要特征的异质性内分泌代谢综合征,这只是一种更复杂的综合征的一种表现,具有显著的全身性影响。证据获取:我们回顾了关于多囊卵巢综合征病理生理和诊断的科学文献,评估了截至2024年6月发表的原始文章、综述和荟萃分析中最相关的数据。证据综合:从病理生理学的角度来看,代谢方面(如胰岛素抵抗和肥胖)和激素改变(如高雄激素血症)的同时可能产生该综合征最相关的临床体征和/症状,如月经不规律、脱发、痤疮和多毛症。近年来,许多证据都强调了家族史和遗传在青春期和成年期综合征发展中的重要性。根据现有资料,维生素D缺乏症可能在多囊卵巢综合征的发病机制和临床表现中起不利作用。结论:多囊卵巢综合征是一种具有挑战性的内分泌和代谢功能障碍,因其在女性中的表达不同,且难以准确诊断。对于受多囊卵巢综合征影响的女性,最合适的方法应该包括一个多步骤的策略,考虑到每个患者的特点,以确定最佳的非药物和药物方法来管理短期、中期和长期的后遗症。
{"title":"Pathophysiology and diagnostic criteria of PCOS.","authors":"Anna Capozzi, Michele Vignali, Giovanni Scambia, Stefano Lello","doi":"10.23736/S2724-606X.24.05612-4","DOIUrl":"10.23736/S2724-606X.24.05612-4","url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic syndrome mainly characterized by ovarian dysfunction, which is only one manifestation of a more complex syndrome with a significant systemic impact.</p><p><strong>Evidence acquisition: </strong>We review scientific literature on the pathophysiology and diagnosis of PCOS evaluating the most relevant data from original articles, reviews and meta-analyses published until June 2024.</p><p><strong>Evidence synthesis: </strong>From a pathophysiological point of view, the concurrence of both metabolic aspects, such as insulin resistance and obesity, and hormonal alterations, such as hyperandrogenemia, might produce the most relevant clinical signs and/symptoms of this syndrome, for instance menstrual irregularities, hair loss, acne and hirsutism. In the latest years, many pieces of evidence highlighted the importance of family history and genetics in the development of the syndrome during adolescence and adult life. According to the available data, hypovitaminosis D could play a detrimental role in the pathogenesis and clinical manifestations of PCOS.</p><p><strong>Conclusions: </strong>PCOS is a challenging endocrine and metabolic dysfunction, due to its different expression among women and to the difficulty in obtaining an accurate diagnosis. The most appropriate approach to women affected by PCOS should involve a multi-step strategy, taking into account the characteristics of each patient, in order to identify the best non-pharmacologic and pharmacologic approach to manage both short- and medium-, and long-term sequelae.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":"361-372"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Explicit consent for episiotomy: recommendations for improving patient communication in prenatal and labor care. 明确同意外阴切开术:改善产前和分娩护理患者沟通的建议。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 DOI: 10.23736/S2724-606X.25.05622-2
Gianluca Montanari Vergallo, Rosagemma Ciliberti, Matteo Gulino

Episiotomy is a common surgical procedure during childbirth that involves incising the woman's perineum to facilitate the passage of the fetus. This procedure is used to speed up the delivery, but only in emergencies. It has been reported that explicit consent is unnecessary when the woman in labor is subresponsive or unresponsive. This manuscript analyzes and describes ethical issues regarding the need for explicit consent to use this procedure. The analysis has been made from two perspectives: applying the principlist approach, a system of biomedical ethics that uses the four bioethical principles formulated by Childress and Beauchamp and the principle of vulnerability in its complex relationship with the concepts of dependence and care as articulated in the Barcelona Declaration of 1998. Based on our analysis, we conclude that explicit consent is a fundamental prerequisite in medical practice that should always be sought, even in complex situations such as performing an episiotomy. A table reporting recommendations to enhance communication with the woman throughout the prenatal phase and during labor has also been provided to improve informed consent processes and ensure more effective patient engagement and decision-making.

会阴切开术是一种常见的分娩手术,包括切开妇女的会阴以促进胎儿的通过。这个程序是用来加快交货速度的,但只在紧急情况下使用。据报道,当分娩中的妇女反应迟钝或没有反应时,明确同意是不必要的。这篇文章分析和描述了关于需要明确同意使用这个程序的伦理问题。分析是从两个角度进行的:应用原则主义方法,这是一种使用Childress和Beauchamp制定的四项生物伦理原则的生物医学伦理体系,以及脆弱性原则与1998年巴塞罗那宣言中阐明的依赖和护理概念的复杂关系。根据我们的分析,我们得出结论,明确同意是医疗实践中应该始终寻求的基本先决条件,即使在执行会阴切开术等复杂情况下也是如此。还提供了一份表格,报告了在整个产前阶段和分娩期间加强与妇女沟通的建议,以改进知情同意程序,确保更有效的患者参与和决策。
{"title":"Explicit consent for episiotomy: recommendations for improving patient communication in prenatal and labor care.","authors":"Gianluca Montanari Vergallo, Rosagemma Ciliberti, Matteo Gulino","doi":"10.23736/S2724-606X.25.05622-2","DOIUrl":"https://doi.org/10.23736/S2724-606X.25.05622-2","url":null,"abstract":"<p><p>Episiotomy is a common surgical procedure during childbirth that involves incising the woman's perineum to facilitate the passage of the fetus. This procedure is used to speed up the delivery, but only in emergencies. It has been reported that explicit consent is unnecessary when the woman in labor is subresponsive or unresponsive. This manuscript analyzes and describes ethical issues regarding the need for explicit consent to use this procedure. The analysis has been made from two perspectives: applying the principlist approach, a system of biomedical ethics that uses the four bioethical principles formulated by Childress and Beauchamp and the principle of vulnerability in its complex relationship with the concepts of dependence and care as articulated in the Barcelona Declaration of 1998. Based on our analysis, we conclude that explicit consent is a fundamental prerequisite in medical practice that should always be sought, even in complex situations such as performing an episiotomy. A table reporting recommendations to enhance communication with the woman throughout the prenatal phase and during labor has also been provided to improve informed consent processes and ensure more effective patient engagement and decision-making.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lifestyle and diet in PCOS. 多囊卵巢综合征患者的生活方式和饮食。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 DOI: 10.23736/S2724-606X.25.05746-X
Anna Capozzi, Giovanni Scambia, Lorenza Driul, Michele Vignali, Stefano Lello

Introduction: Polycystic ovary syndrome (PCOS) is a multifactorial endocrine-metabolic disease that requires pharmacological and non-pharmacological treatments. The aim of this paper is to review the major evidence about current lifestyle and dietary approaches to manage this syndrome.

Evidence acquisition: We include in our research the most relevant publications about lifestyle and diet in PCOS published between 1995 and 2025.

Evidence synthesis: According to the most recent recommendations, regular physical activity is crucial to ameliorate hormonal and metabolic parameters as well as to maintain and/or reduce weight in PCOS women. As for the foods, although there is not agreement on a specific diet, low-glycemic index nutrients associated with high fiber intake should be generally preferred in hyperinsulinemic patients.

Conclusions: In conclusion, suggestions about lifestyle and diet should represent a cornerstone of the personalized multi-step therapy of PCOS.

简介:多囊卵巢综合征(PCOS)是一种多因素内分泌代谢疾病,需要药物和非药物治疗。本文的目的是回顾有关当前生活方式和饮食方法管理该综合征的主要证据。证据获取:我们的研究纳入了1995年至2025年间发表的关于多囊卵巢综合征生活方式和饮食的最相关出版物。证据综合:根据最近的建议,有规律的体育活动对于改善多囊卵巢综合征妇女的激素和代谢参数以及维持和/或减轻体重至关重要。至于食物,虽然对具体的饮食没有一致的意见,但对于高胰岛素血症患者,通常应优先选择与高纤维摄入相关的低血糖指数营养素。结论:生活方式和饮食建议应成为多囊卵巢综合征个性化多步骤治疗的基石。
{"title":"Lifestyle and diet in PCOS.","authors":"Anna Capozzi, Giovanni Scambia, Lorenza Driul, Michele Vignali, Stefano Lello","doi":"10.23736/S2724-606X.25.05746-X","DOIUrl":"10.23736/S2724-606X.25.05746-X","url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is a multifactorial endocrine-metabolic disease that requires pharmacological and non-pharmacological treatments. The aim of this paper is to review the major evidence about current lifestyle and dietary approaches to manage this syndrome.</p><p><strong>Evidence acquisition: </strong>We include in our research the most relevant publications about lifestyle and diet in PCOS published between 1995 and 2025.</p><p><strong>Evidence synthesis: </strong>According to the most recent recommendations, regular physical activity is crucial to ameliorate hormonal and metabolic parameters as well as to maintain and/or reduce weight in PCOS women. As for the foods, although there is not agreement on a specific diet, low-glycemic index nutrients associated with high fiber intake should be generally preferred in hyperinsulinemic patients.</p><p><strong>Conclusions: </strong>In conclusion, suggestions about lifestyle and diet should represent a cornerstone of the personalized multi-step therapy of PCOS.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":"341-351"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiometabolic risk in women with polycystic ovary syndrome: a comprehensive review. 多囊卵巢综合征妇女的心脏代谢风险:一项全面的综述。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 DOI: 10.23736/S2724-606X.25.05732-X
Angelo Cagnacci, Gino A Antonelli, Giulia Vatteroni, Anjeza Xholli

Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women, which is associated with a significantly higher risk of developing cardiometabolic abnormalities. The present review is aimed to understand the different mechanism related to the cardiometabolic alteration of women with PCOS.

Evidence acquisition: A literature search was made on terms encompassing PCOS, hyperandrogenism, obesity, lipid metabolism, insulin resistance, inflammation, oxidative stress, gut microbiota, cardiovascular event, and mortality.

Evidence synthesis: Hyperandrogenism is the key signature of women with PCOS. Androgens by reducing the intracellular signal of insulin, induce an insulin resistance that is compensated by hyperinsulinemia. Hyperinsulinemia and insulin resistance are the key determinants of the metabolic syndrome and therefore of the cardiovascular risk. Obesity, oxidative stress and chronic inflammation further increase insulin resistance and represent adjunctive pejorative risk factors. Modification of gut microbiota is common in women with PCOS, and it is consequent to hyperandrogenism and obesity. Gut dysbiosis contributes to induce metabolic alterations. In women with PCOS the cardiovascular risk depends upon syndrome manifestation. The risk is maximal in hyperandrogenic obese anovulatory women, milder in hyperandrogenic non obese women, and is not increased in non-hyperandrogenic PCOS women.

Conclusions: Among PCOS women, phenotypes characterized by hyperandrogenism, anovulation and obesity are at high risk of cardiometabolic alterations. In general, a careful investigation on the presence of cardiovascular risk factors, and the use of appropriate remedies to reduce them, is useful in all PCOS women with hyperandrogenism, and in particular in those with associated anovulation and obesity.

简介:多囊卵巢综合征(PCOS)是一种影响育龄妇女的常见内分泌疾病,与发生心脏代谢异常的风险显著增高有关。本综述旨在了解与PCOS女性心脏代谢改变相关的不同机制。证据获取:文献检索包括多囊卵巢综合征、高雄激素症、肥胖、脂质代谢、胰岛素抵抗、炎症、氧化应激、肠道微生物群、心血管事件和死亡率。证据综合:雄激素过多是多囊卵巢综合征女性的关键特征。雄激素通过减少细胞内胰岛素信号,诱导胰岛素抵抗,并通过高胰岛素血症进行补偿。高胰岛素血症和胰岛素抵抗是代谢综合征和心血管风险的关键决定因素。肥胖、氧化应激和慢性炎症进一步增加胰岛素抵抗,是辅助性的不良危险因素。肠道菌群的改变在多囊卵巢综合征的女性中很常见,这是高雄激素症和肥胖的结果。肠道生态失调有助于诱导代谢改变。多囊卵巢综合征女性的心血管风险取决于综合征的表现。高雄激素性肥胖无排卵妇女的风险最大,高雄激素性非肥胖妇女的风险较轻,而非高雄激素性多囊卵巢综合征妇女的风险不增加。结论:在PCOS女性中,以高雄激素、无排卵和肥胖为特征的表型是心脏代谢改变的高风险。总的来说,仔细调查心血管危险因素的存在,并使用适当的补救措施来减少它们,对所有伴有雄激素过多的多囊卵巢综合征妇女,特别是那些伴有排卵和肥胖的妇女是有用的。
{"title":"Cardiometabolic risk in women with polycystic ovary syndrome: a comprehensive review.","authors":"Angelo Cagnacci, Gino A Antonelli, Giulia Vatteroni, Anjeza Xholli","doi":"10.23736/S2724-606X.25.05732-X","DOIUrl":"10.23736/S2724-606X.25.05732-X","url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women, which is associated with a significantly higher risk of developing cardiometabolic abnormalities. The present review is aimed to understand the different mechanism related to the cardiometabolic alteration of women with PCOS.</p><p><strong>Evidence acquisition: </strong>A literature search was made on terms encompassing PCOS, hyperandrogenism, obesity, lipid metabolism, insulin resistance, inflammation, oxidative stress, gut microbiota, cardiovascular event, and mortality.</p><p><strong>Evidence synthesis: </strong>Hyperandrogenism is the key signature of women with PCOS. Androgens by reducing the intracellular signal of insulin, induce an insulin resistance that is compensated by hyperinsulinemia. Hyperinsulinemia and insulin resistance are the key determinants of the metabolic syndrome and therefore of the cardiovascular risk. Obesity, oxidative stress and chronic inflammation further increase insulin resistance and represent adjunctive pejorative risk factors. Modification of gut microbiota is common in women with PCOS, and it is consequent to hyperandrogenism and obesity. Gut dysbiosis contributes to induce metabolic alterations. In women with PCOS the cardiovascular risk depends upon syndrome manifestation. The risk is maximal in hyperandrogenic obese anovulatory women, milder in hyperandrogenic non obese women, and is not increased in non-hyperandrogenic PCOS women.</p><p><strong>Conclusions: </strong>Among PCOS women, phenotypes characterized by hyperandrogenism, anovulation and obesity are at high risk of cardiometabolic alterations. In general, a careful investigation on the presence of cardiovascular risk factors, and the use of appropriate remedies to reduce them, is useful in all PCOS women with hyperandrogenism, and in particular in those with associated anovulation and obesity.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":"393-406"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postnatal outcomes and surgical management of prenatally detected unilateral congenital anomalies of the kidney and urinary tract. 产前发现单侧先天性肾脏和尿路异常的产后结局和手术处理。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 DOI: 10.23736/S2724-606X.25.05702-1
Marta Fiorentini, Bianca Nedu, Sara Doroldi, Clotilde Mattarelli, Francesca Petrillo, Gianluigi Pilu, Elisa Montaguti

Background: Congenital anomalies of the kidney and urinary tract (CAKUT) represent 15-20% of prenatally diagnosed congenital anomalies, often presenting unilaterally. This study aimed to describe sonographic features of fetuses with unilateral renal anomalies and evaluate their postnatal outcomes. Additionally, we assessed whether specific prenatal ultrasound findings predicted postnatal complications.

Methods: This was a retrospective, observational study including singleton pregnancies referred to our center from 2008 to 2023 for unilateral renal anomalies identified in second or third trimester ultrasounds. Sequential prenatal ultrasound evaluations were conducted to monitor disease progression and associated anomalies. Postnatal outcomes were retrieved from delivery records and pediatric follow-ups. Statistical analyses included Chi-square tests, t-tests, and ROC curve analysis to assess the predictive value of the antero-posterior diameter (DAP) of the renal pelvis for postnatal complications.

Results: A total of 226 cases were included: 116 (51.3%) pyelectases, 51 (22.6%) hydroureteronephroses, 48 (21.2%) multicystic kidneys, and 11 (4.9%) renal dysplasias. Diagnosis occurred at an average gestational age of 25 weeks, with 19.3% showing progression during pregnancy and 23% having associated anomalies detected during ultrasound examinations. Of 135 children with follow-up data, 47.4% required surgery, 1.5% developed hypertension, and 1.5% developed chronic kidney disease (CKD). Associated anomalies significantly correlated with unfavorable outcomes, such as need for intervention (P=0.001), risk of developing postnatal recurrent urinary infections (P=0.025), vesicoureteral reflux (P=0.001) and CKD (P=0.010). Progression during pregnancy correlated with vesicoureteral reflux (P=0.002) and development of anomalies in the contralateral kidney (P=0.012). DAP measurement did not reliably predict postnatal complications (AUC=0.590, P=0.191).

Conclusions: Unilateral renal anomalies are often associated with other congenital anomalies, influencing postnatal outcomes. DAP measurement was not a significant predictor of postnatal complications. Comprehensive prenatal ultrasound assessments are critical for guiding parental counseling, pregnancy management, and postnatal care.

背景:先天性肾和尿路异常(ckut)占产前诊断先天性异常的15-20%,通常单侧表现。本研究旨在描述单侧肾脏异常胎儿的声像图特征并评估其产后预后。此外,我们评估了特定的产前超声结果是否可以预测产后并发症。方法:这是一项回顾性观察性研究,包括2008年至2023年期间在妊娠中期或晚期超声检查中发现的单侧肾脏异常的单胎妊娠。序贯产前超声评估监测疾病进展和相关异常。从分娩记录和儿科随访中检索产后结果。统计学分析采用卡方检验、t检验、ROC曲线分析评价肾盂前后径(DAP)对产后并发症的预测价值。结果:共226例:肾盂肿大116例(51.3%),肾盂积水51例(22.6%),多囊肾48例(21.2%),肾发育不良11例(4.9%)。诊断发生在平均胎龄为25周时,19.3%的患者在妊娠期间出现进展,23%的患者在超声检查中发现相关异常。在135名随访儿童中,47.4%需要手术,1.5%发展为高血压,1.5%发展为慢性肾脏疾病(CKD)。相关异常与不良结局显著相关,如需要干预(P=0.001)、发生产后复发性尿路感染(P=0.025)、膀胱输尿管反流(P=0.001)和CKD (P=0.010)。妊娠期间的进展与膀胱输尿管反流(P=0.002)和对侧肾脏异常的发生相关(P=0.012)。DAP测量不能可靠地预测产后并发症(AUC=0.590, P=0.191)。结论:单侧肾异常常伴有其他先天性异常,影响产后预后。DAP测量并不是产后并发症的显著预测因子。全面的产前超声评估对指导父母咨询、妊娠管理和产后护理至关重要。
{"title":"Postnatal outcomes and surgical management of prenatally detected unilateral congenital anomalies of the kidney and urinary tract.","authors":"Marta Fiorentini, Bianca Nedu, Sara Doroldi, Clotilde Mattarelli, Francesca Petrillo, Gianluigi Pilu, Elisa Montaguti","doi":"10.23736/S2724-606X.25.05702-1","DOIUrl":"https://doi.org/10.23736/S2724-606X.25.05702-1","url":null,"abstract":"<p><strong>Background: </strong>Congenital anomalies of the kidney and urinary tract (CAKUT) represent 15-20% of prenatally diagnosed congenital anomalies, often presenting unilaterally. This study aimed to describe sonographic features of fetuses with unilateral renal anomalies and evaluate their postnatal outcomes. Additionally, we assessed whether specific prenatal ultrasound findings predicted postnatal complications.</p><p><strong>Methods: </strong>This was a retrospective, observational study including singleton pregnancies referred to our center from 2008 to 2023 for unilateral renal anomalies identified in second or third trimester ultrasounds. Sequential prenatal ultrasound evaluations were conducted to monitor disease progression and associated anomalies. Postnatal outcomes were retrieved from delivery records and pediatric follow-ups. Statistical analyses included Chi-square tests, t-tests, and ROC curve analysis to assess the predictive value of the antero-posterior diameter (DAP) of the renal pelvis for postnatal complications.</p><p><strong>Results: </strong>A total of 226 cases were included: 116 (51.3%) pyelectases, 51 (22.6%) hydroureteronephroses, 48 (21.2%) multicystic kidneys, and 11 (4.9%) renal dysplasias. Diagnosis occurred at an average gestational age of 25 weeks, with 19.3% showing progression during pregnancy and 23% having associated anomalies detected during ultrasound examinations. Of 135 children with follow-up data, 47.4% required surgery, 1.5% developed hypertension, and 1.5% developed chronic kidney disease (CKD). Associated anomalies significantly correlated with unfavorable outcomes, such as need for intervention (P=0.001), risk of developing postnatal recurrent urinary infections (P=0.025), vesicoureteral reflux (P=0.001) and CKD (P=0.010). Progression during pregnancy correlated with vesicoureteral reflux (P=0.002) and development of anomalies in the contralateral kidney (P=0.012). DAP measurement did not reliably predict postnatal complications (AUC=0.590, P=0.191).</p><p><strong>Conclusions: </strong>Unilateral renal anomalies are often associated with other congenital anomalies, influencing postnatal outcomes. DAP measurement was not a significant predictor of postnatal complications. Comprehensive prenatal ultrasound assessments are critical for guiding parental counseling, pregnancy management, and postnatal care.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polycystic ovary syndrome as a risk factor for cancer. 多囊卵巢综合征是癌症的危险因素。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-25 DOI: 10.23736/S2724-606X.25.05719-7
Alessandro Gambera, Giulia Rodondi, Giulia Oliveri, Federico Ferrari, Michele Vignali, Anna Fichera, Franco Odicino

Introduction: Polycystic ovary syndrome (PCOS) is a common endocrinological disorder and is frequently associated with other medical conditions such as hyperinsulinemia and obesity. The aim of this review is to identify the role of PCOS as a potential risk factor for endometrial, breast and ovarian cancer.

Evidence acquisition: A literature search was conducted including most relevant peer-reviewed articles regarding the possible association between PCOS and gynecological cancer published from 1996 to the present.

Evidence synthesis: A narrative synthesis was performed. PCOS is linked to an increased risk of endometrial cancer. However, the risk varies based on factors like BMI, parity, and phenotype. The association between PCOS and ovarian cancer is uncertain. Some studies suggest a two-fold increased risk, particularly in women with infertility or treated for infertility, but more recent reviews find no clear association. The role of androgen and estrogen imbalances in different ovarian cancer types remains debated. Even the link between PCOS and breast cancer is unclear. While high androgen levels are theorized to play a role, local hormone conversion and factors like weight, environment, and genetics are likely more important.

Conclusions: The association between PCOS and gynecological cancers is complex. Further reviews and new studies that control individual confounding factors are needed to accurately establish the real oncological risk of PCOS.

简介:多囊卵巢综合征(PCOS)是一种常见的内分泌紊乱,通常与高胰岛素血症和肥胖等其他疾病相关。本综述的目的是确定多囊卵巢综合征作为子宫内膜癌、乳腺癌和卵巢癌的潜在危险因素的作用。证据获取:检索了1996年至今发表的关于多囊卵巢综合征与妇科癌症之间可能存在关联的大多数相关同行评议文章。证据综合:进行叙述综合。多囊卵巢综合征与子宫内膜癌的风险增加有关。然而,风险因BMI、胎次和表型等因素而异。多囊卵巢综合征与卵巢癌之间的关系尚不确定。一些研究表明,风险增加了两倍,特别是在不孕或接受不孕治疗的妇女中,但最近的评论没有发现明确的关联。雄激素和雌激素失衡在不同类型卵巢癌中的作用仍有争议。甚至多囊卵巢综合征和乳腺癌之间的联系也不清楚。虽然高雄激素水平在理论上起作用,但局部激素转换和体重、环境和遗传等因素可能更重要。结论:多囊卵巢综合征与妇科肿瘤的关系是复杂的。需要进一步的综述和新的研究来控制个体混杂因素,以准确地确定多囊卵巢综合征的真正肿瘤风险。
{"title":"Polycystic ovary syndrome as a risk factor for cancer.","authors":"Alessandro Gambera, Giulia Rodondi, Giulia Oliveri, Federico Ferrari, Michele Vignali, Anna Fichera, Franco Odicino","doi":"10.23736/S2724-606X.25.05719-7","DOIUrl":"10.23736/S2724-606X.25.05719-7","url":null,"abstract":"<p><strong>Introduction: </strong>Polycystic ovary syndrome (PCOS) is a common endocrinological disorder and is frequently associated with other medical conditions such as hyperinsulinemia and obesity. The aim of this review is to identify the role of PCOS as a potential risk factor for endometrial, breast and ovarian cancer.</p><p><strong>Evidence acquisition: </strong>A literature search was conducted including most relevant peer-reviewed articles regarding the possible association between PCOS and gynecological cancer published from 1996 to the present.</p><p><strong>Evidence synthesis: </strong>A narrative synthesis was performed. PCOS is linked to an increased risk of endometrial cancer. However, the risk varies based on factors like BMI, parity, and phenotype. The association between PCOS and ovarian cancer is uncertain. Some studies suggest a two-fold increased risk, particularly in women with infertility or treated for infertility, but more recent reviews find no clear association. The role of androgen and estrogen imbalances in different ovarian cancer types remains debated. Even the link between PCOS and breast cancer is unclear. While high androgen levels are theorized to play a role, local hormone conversion and factors like weight, environment, and genetics are likely more important.</p><p><strong>Conclusions: </strong>The association between PCOS and gynecological cancers is complex. Further reviews and new studies that control individual confounding factors are needed to accurately establish the real oncological risk of PCOS.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":"385-392"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Granulosa-cumulus cells global transcriptome sequencing as a predictor of embryo development: a preliminary study. 颗粒-积云细胞全球转录组测序作为胚胎发育的预测因子:初步研究。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-10-01 Epub Date: 2025-07-30 DOI: 10.23736/S2724-606X.25.05765-3
Raoul Orvieto, Louisa Cohen, Chen Shimon, Adva Aizer, Efrat Glick Saar, Dan Dominissini, Omri Nayshool

Background: The aim of this study is to determine the human oocyte CCs global transcriptome sequencing and its correlation of embryo development to the blastocyst-stage.

Methods: Expanded cumulus granulosa cells (CGC) that surround metaphase 2 were collected and cryopreserved until analysis. Their corresponding oocytes trajectories were followed up to the blastocyst stage. From each patient, CGCs of oocyte that developed to the blastocyst stage and one that was arrested (sibling oocytes) were analyzed. Global transcriptome sequencing (NEBNext® Single Cell/Low Input RNA Library Prep Kit for Illumina) was compared between CGCs of oocytes that developed to the blastocyst stage and those that were arrested.

Results: Seven patients aged 31.4+2.5 years donated CGCs. The Differential Gene Expression Analysis identified five genes that were differentially expressed between blastocyst and arrested CGCs. The most significantly differentially expressed gene was AL031598.1 (padj = 8.40e-03, log2FC = 5.76), followed by AC126773.5 (padj = 1.83e-02, log2FC = 6.63), CBLN2 (padj = 2.62e-02, log2FC = -6.24), AL022721.1 (padj = 3.28e-02, log2FC = 5.73), and AC093334.1 (padj = 8.53e-02, log2FC = 6.07). Among these genes, CBLN2 was the only one showing significant downregulation in the blastocyst group, while the other four genes demonstrated substantial upregulation.

Conclusions: This study provides valuable insights into the transcriptional landscape of CGC from oocytes that develop to different stages, revealing key genes and long non-coding RNAs that may serve as markers for oocyte quality and its potential to develop to the blastocyst stage. Future research with larger cohorts and independent validation methods is necessary to confirm these findings and their potential application in fertility treatments.

背景:本研究的目的是确定人卵母细胞CCs全球转录组测序及其与胚胎发育与囊胚期的相关性。方法:收集中期2周围扩增的积云颗粒细胞(CGC),冷冻保存至分析。相应的卵母细胞轨迹被跟踪到囊胚期。分析每位患者发育到囊胚期的卵母细胞和阻滞期的卵母细胞(同胞卵母细胞)的CGCs。通过全球转录组测序(NEBNext®单细胞/低输入RNA库准备试剂盒for Illumina)比较发育到囊胚期的卵母细胞和阻滞期的卵母细胞的cgc。结果:7例患者(31.4+2.5岁)捐献了cgc。差异基因表达分析鉴定了5个基因在囊胚和阻滞cgc之间的差异表达。差异表达最显著的基因为AL031598.1 (padj = 8.400e -03, log2FC = 5.76),其次为AC126773.5 (padj = 1.83e-02, log2FC = 6.63)、CBLN2 (padj = 2.62e-02, log2FC = -6.24)、AL022721.1 (padj = 3.28e-02, log2FC = 5.73)和AC093334.1 (padj = 8.53e-02, log2FC = 6.07)。在这些基因中,CBLN2是囊胚组中唯一显著下调的基因,其他4个基因均显著上调。结论:本研究为了解发育到不同阶段的卵母细胞的CGC转录图谱提供了有价值的见解,揭示了可能作为卵母细胞质量及其发育到囊胚阶段潜力标记的关键基因和长链非编码rna。未来的研究需要更大的队列和独立的验证方法来证实这些发现及其在生育治疗中的潜在应用。
{"title":"Granulosa-cumulus cells global transcriptome sequencing as a predictor of embryo development: a preliminary study.","authors":"Raoul Orvieto, Louisa Cohen, Chen Shimon, Adva Aizer, Efrat Glick Saar, Dan Dominissini, Omri Nayshool","doi":"10.23736/S2724-606X.25.05765-3","DOIUrl":"10.23736/S2724-606X.25.05765-3","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to determine the human oocyte CCs global transcriptome sequencing and its correlation of embryo development to the blastocyst-stage.</p><p><strong>Methods: </strong>Expanded cumulus granulosa cells (CGC) that surround metaphase 2 were collected and cryopreserved until analysis. Their corresponding oocytes trajectories were followed up to the blastocyst stage. From each patient, CGCs of oocyte that developed to the blastocyst stage and one that was arrested (sibling oocytes) were analyzed. Global transcriptome sequencing (NEBNext<sup>®</sup> Single Cell/Low Input RNA Library Prep Kit for Illumina) was compared between CGCs of oocytes that developed to the blastocyst stage and those that were arrested.</p><p><strong>Results: </strong>Seven patients aged 31.4+2.5 years donated CGCs. The Differential Gene Expression Analysis identified five genes that were differentially expressed between blastocyst and arrested CGCs. The most significantly differentially expressed gene was AL031598.1 (padj = 8.40e-03, log2FC = 5.76), followed by AC126773.5 (padj = 1.83e-02, log2FC = 6.63), CBLN2 (padj = 2.62e-02, log2FC = -6.24), AL022721.1 (padj = 3.28e-02, log2FC = 5.73), and AC093334.1 (padj = 8.53e-02, log2FC = 6.07). Among these genes, CBLN2 was the only one showing significant downregulation in the blastocyst group, while the other four genes demonstrated substantial upregulation.</p><p><strong>Conclusions: </strong>This study provides valuable insights into the transcriptional landscape of CGC from oocytes that develop to different stages, revealing key genes and long non-coding RNAs that may serve as markers for oocyte quality and its potential to develop to the blastocyst stage. Future research with larger cohorts and independent validation methods is necessary to confirm these findings and their potential application in fertility treatments.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":"415-423"},"PeriodicalIF":1.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant radiotherapy for early-stage endometrial cancer based on randomized controlled trials: a narrative review. 基于随机对照试验的早期子宫内膜癌辅助放疗:叙述性回顾。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-12 DOI: 10.23736/S2724-606X.25.05723-9
Gabriel Levin, Susie Lau, Shannon Salvador, Melica Brodeur, Raanan Meyer, Walter Gotlieb

Endometrial carcinoma (EC) is the most common gynecologic malignancy in the USA, with surgical staging as the cornerstone of treatment. Although most patients are diagnosed at an early stage, adjuvant therapies, including external beam radiation therapy (EBRT), vaginal brachytherapy (VBT), and systemic treatments, are employed in select cases to reduce recurrence risk. This review highlights data from randomized controlled trials assessing the efficacy of adjuvant radiotherapy in early-stage EC. For low-risk EC, studies suggest that postoperative brachytherapy has minimal impact on locoregional recurrence and is not recommended without significant uterine risk factors. In intermediate-risk EC, trials such as GOG 99 and PORTEC-1 demonstrated reduced recurrence with pelvic RT, particularly in high-intermediate risk subsets, though overall survival benefits were not observed. For high-intermediate risk EC, PORTEC-2 showed that VBT effectively controls vaginal recurrence with less morbidity compared to EBRT, recommending VBT as the preferred modality. Medium-risk cases benefit similarly from VBT alone, as shown in Swedish trials. In high-risk EC, RCTs such as GOG 249 and PORTEC-3 examined the addition of chemotherapy to radiotherapy, finding comparable recurrence and survival outcomes between VBT with chemotherapy and EBRT, though acute toxicity was higher with combined therapy. Across these trials, the degree of lymphovascular space invasion (LVSI), patient age, tumor grade, and histology were key prognostic factors influencing treatment recommendations. Despite advancements in molecular classification and modern radiotherapy techniques, most data derive from earlier studies, emphasizing the need for updated research to refine treatment paradigms.

子宫内膜癌(EC)是美国最常见的妇科恶性肿瘤,手术分期是治疗的基石。虽然大多数患者在早期被诊断出来,但辅助治疗,包括外束放射治疗(EBRT),阴道近距离治疗(VBT)和全身治疗,在选定的病例中采用,以降低复发风险。这篇综述强调了评估早期EC辅助放疗疗效的随机对照试验的数据。对于低风险的EC,研究表明术后近距离放疗对局部复发的影响很小,如果没有明显的子宫危险因素,不推荐使用。在中等风险的EC中,GOG 99和PORTEC-1等试验显示盆腔RT的复发率降低,特别是在中高风险亚群中,尽管没有观察到总体生存获益。对于中高风险EC, PORTEC-2显示VBT与EBRT相比可有效控制阴道复发,且发病率更低,推荐VBT作为首选方式。瑞典的试验表明,中等风险病例单独使用VBT也有类似的益处。在高风险EC中,GOG 249和porc -3等随机对照试验检查了化疗对放疗的补充,发现VBT联合化疗和EBRT之间的复发和生存结果相当,尽管联合治疗的急性毒性更高。在这些试验中,淋巴血管间隙侵袭程度(LVSI)、患者年龄、肿瘤分级和组织学是影响治疗建议的关键预后因素。尽管分子分类和现代放射治疗技术取得了进步,但大多数数据来自早期研究,强调需要更新研究以完善治疗范例。
{"title":"Adjuvant radiotherapy for early-stage endometrial cancer based on randomized controlled trials: a narrative review.","authors":"Gabriel Levin, Susie Lau, Shannon Salvador, Melica Brodeur, Raanan Meyer, Walter Gotlieb","doi":"10.23736/S2724-606X.25.05723-9","DOIUrl":"https://doi.org/10.23736/S2724-606X.25.05723-9","url":null,"abstract":"<p><p>Endometrial carcinoma (EC) is the most common gynecologic malignancy in the USA, with surgical staging as the cornerstone of treatment. Although most patients are diagnosed at an early stage, adjuvant therapies, including external beam radiation therapy (EBRT), vaginal brachytherapy (VBT), and systemic treatments, are employed in select cases to reduce recurrence risk. This review highlights data from randomized controlled trials assessing the efficacy of adjuvant radiotherapy in early-stage EC. For low-risk EC, studies suggest that postoperative brachytherapy has minimal impact on locoregional recurrence and is not recommended without significant uterine risk factors. In intermediate-risk EC, trials such as GOG 99 and PORTEC-1 demonstrated reduced recurrence with pelvic RT, particularly in high-intermediate risk subsets, though overall survival benefits were not observed. For high-intermediate risk EC, PORTEC-2 showed that VBT effectively controls vaginal recurrence with less morbidity compared to EBRT, recommending VBT as the preferred modality. Medium-risk cases benefit similarly from VBT alone, as shown in Swedish trials. In high-risk EC, RCTs such as GOG 249 and PORTEC-3 examined the addition of chemotherapy to radiotherapy, finding comparable recurrence and survival outcomes between VBT with chemotherapy and EBRT, though acute toxicity was higher with combined therapy. Across these trials, the degree of lymphovascular space invasion (LVSI), patient age, tumor grade, and histology were key prognostic factors influencing treatment recommendations. Despite advancements in molecular classification and modern radiotherapy techniques, most data derive from earlier studies, emphasizing the need for updated research to refine treatment paradigms.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Residual tumor using CT scan based on modified radiologic Lakhman Index after optimal cytoreduction in advanced ovarian cancer: advantages of a simplified method. 基于改进放射学Lakhman指数的晚期卵巢癌最佳细胞减少后残余肿瘤CT扫描:一种简化方法的优点。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-12 DOI: 10.23736/S2724-606X.25.05771-9
Alexandra Trelis Blanes, Víctor Lago, Vicente Belloch Ripollés, Rosario Pérez Martínez, Guillermina Montoliu, Pablo Padilla Iserte, Marta Gurrea, Jose M Cardenas Rebollo, Santiago Domingo

Background: Advanced ovarian cancer is the deadliest gynecological malignancy, with treatment combining cytoreductive surgery and platinum/taxane chemotherapy. Surgical success is defined by residual tumor size, but visual assessment may underestimate residual disease. Postoperative computed tomography (CT) scans can detect residual tumors in up to 49% of cases initially deemed tumor-free. Structured radiologic reporting, such as the Peritoneal Carcinomatosis Index (PCI), improves accuracy and prognosis correlation. This study aims to validate a simplified structured reporting method based on the Lakhman index.

Methods: Patients with advanced ovarian cancer (FIGO stages II and IV) diagnosed between 2007 and 2019 at Hospital La Fe Valencia were included in the study. All underwent cytoreductive surgery with R0 or R1 outcomes, followed by a postoperative CT scan performed between the third and eighth weeks after surgery and before the initiation of chemotherapy. Two gynecologic oncology-specialized radiologists independently analyzed the CT scans in a double-blind manner. They assessed the images using the Lakhman Index, which divides the abdominopelvic cavity into eight regions. Additionally, they applied the Qualitative Assessment (QA) scale to determine the presence of tumor disease in each region, classifying them as QA 1-2 (definitely/probably normal), QA 3 (indeterminate) and QA 4-5 (probably/definitely metastatic).

Results: The study analyzed a cohort of 117 patients. Radiological evaluation detected macroscopic measurable tumor disease in 44%-49% of patients following optimal primary cytoreduction (R0 or R1). Kappa analysis showed a moderate level of concordance between the two radiologists (0.589). Findings from both radiologists (A and B) were significantly associated with reduced disease-free survival (DFS) and overall survival (OS) in patients with macroscopic disease compared to those without (P<0.05).

Conclusions: The identification of radiological tumor presence on standardized, systematic postoperative CT scans prior to adjuvant chemotherapy is linked to the prognosis of patients with advanced ovarian cancer.

背景:晚期卵巢癌是最致命的妇科恶性肿瘤,治疗方法包括细胞减缩手术和铂/紫杉烷化疗。手术成功是由残留肿瘤大小决定的,但视觉评估可能低估残留疾病。术后计算机断层扫描(CT)可以在高达49%的最初认为无肿瘤的病例中检测到残留肿瘤。结构化的放射学报告,如腹膜癌指数(PCI),提高了准确性和预后相关性。本研究旨在验证一种基于Lakhman指数的简化结构化报告方法。方法:纳入2007年至2019年在La Fe Valencia医院诊断的晚期卵巢癌(FIGO II期和IV期)患者。所有患者均接受了R0或R1结果的细胞减少手术,随后在手术后第3周至第8周和化疗开始前进行了术后CT扫描。两名妇科肿瘤专科放射科医生以双盲方式独立分析了CT扫描结果。他们使用拉克曼指数(Lakhman Index)来评估这些图像,该指数将腹部骨盆划分为八个区域。此外,他们应用定性评估(QA)量表来确定每个区域是否存在肿瘤疾病,将其分为QA 1-2(肯定/可能正常),QA 3(不确定)和QA 4-5(可能/肯定转移)。结果:该研究分析了117例患者。在原发细胞减数(R0或R1)达到最佳水平的患者中,44%-49%的患者放射学评估发现了宏观可测量的肿瘤疾病。Kappa分析显示两名放射科医生之间的一致性为中等水平(0.589)。来自放射科医生(A和B)的研究结果与无宏观疾病患者的无病生存期(DFS)和总生存期(OS)显著相关。结论:辅助化疗前标准化、系统的术后CT扫描放射学肿瘤存在的识别与晚期卵巢癌患者的预后有关。
{"title":"Residual tumor using CT scan based on modified radiologic Lakhman Index after optimal cytoreduction in advanced ovarian cancer: advantages of a simplified method.","authors":"Alexandra Trelis Blanes, Víctor Lago, Vicente Belloch Ripollés, Rosario Pérez Martínez, Guillermina Montoliu, Pablo Padilla Iserte, Marta Gurrea, Jose M Cardenas Rebollo, Santiago Domingo","doi":"10.23736/S2724-606X.25.05771-9","DOIUrl":"https://doi.org/10.23736/S2724-606X.25.05771-9","url":null,"abstract":"<p><strong>Background: </strong>Advanced ovarian cancer is the deadliest gynecological malignancy, with treatment combining cytoreductive surgery and platinum/taxane chemotherapy. Surgical success is defined by residual tumor size, but visual assessment may underestimate residual disease. Postoperative computed tomography (CT) scans can detect residual tumors in up to 49% of cases initially deemed tumor-free. Structured radiologic reporting, such as the Peritoneal Carcinomatosis Index (PCI), improves accuracy and prognosis correlation. This study aims to validate a simplified structured reporting method based on the Lakhman index.</p><p><strong>Methods: </strong>Patients with advanced ovarian cancer (FIGO stages II and IV) diagnosed between 2007 and 2019 at Hospital La Fe Valencia were included in the study. All underwent cytoreductive surgery with R0 or R1 outcomes, followed by a postoperative CT scan performed between the third and eighth weeks after surgery and before the initiation of chemotherapy. Two gynecologic oncology-specialized radiologists independently analyzed the CT scans in a double-blind manner. They assessed the images using the Lakhman Index, which divides the abdominopelvic cavity into eight regions. Additionally, they applied the Qualitative Assessment (QA) scale to determine the presence of tumor disease in each region, classifying them as QA 1-2 (definitely/probably normal), QA 3 (indeterminate) and QA 4-5 (probably/definitely metastatic).</p><p><strong>Results: </strong>The study analyzed a cohort of 117 patients. Radiological evaluation detected macroscopic measurable tumor disease in 44%-49% of patients following optimal primary cytoreduction (R0 or R1). Kappa analysis showed a moderate level of concordance between the two radiologists (0.589). Findings from both radiologists (A and B) were significantly associated with reduced disease-free survival (DFS) and overall survival (OS) in patients with macroscopic disease compared to those without (P<0.05).</p><p><strong>Conclusions: </strong>The identification of radiological tumor presence on standardized, systematic postoperative CT scans prior to adjuvant chemotherapy is linked to the prognosis of patients with advanced ovarian cancer.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medically-assisted reproduction in Italy, 2021 data from the Italian MAR Registry. 意大利的医疗辅助生殖,2021年数据来自意大利MAR登记处。
IF 1 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2025-09-05 DOI: 10.23736/S2724-606X.25.05799-9
Vincenzo Vigiliano, Giulia Scaravelli, Roberta Spoletini, Lucia Speziale, Fabiola Fedele, Simone Bolli, Monica Mazzola, Anna Bertini, Roberto DE Luca

Background: The Italian Medically Assisted Reproduction Registry (ItMARR) was established by a Decree of the Minister of Health issued on October 7th, 2005. ItMARR has a crucial role in clearly and publicly disseminating epidemiological information on MAR activities and outcomes.

Methods: ItMARR data are collected in aggregate form and their submission is mandatory as stipulated by Law 40/2004. The aim of this article is to make a comprehensive overview of the activity of authorized centers that perform IUI and ART in Italy. Data used in this article refer to MAR treatments started between January 1st and December 31st, 2021.

Results: MAR techniques were performed by 340 centers. In total, 92,407 ART cycles and 15,660 IUI cycles were performed in 2021. Gametes donation cycles represent 14.6% of ART activity and 4.2% of IUI. ART cycles performed per million women of childbearing age were 9077. In 2021, 3.8% of births in the general population in Italy were a result of ART application. In 2021, MAR activity had a strong increase compared to the previous year in which there were strong limitations on reproductive treatments due to the COVID-19 pandemic. Pregnancy rates per transfers were 29.4% with fresh techniques, 35.2% with FER, 26.3% with FO, 41.2% with OD and 37.9% with SD. The decreasing trend of multiple deliveries continues.

Conclusions: The ItMARR has become a great asset in the reproductive health scenario promoting a better MAR information dissemination. ItMARR is working on the implementation towards a "cycle-by-cycle" data collection system. This will bring the Italian monitoring system in line with others European countries.

背景:意大利医疗辅助生殖登记处(ItMARR)是根据卫生部2005年10月7日发布的一项法令设立的。在明确和公开地传播关于MAR活动和结果的流行病学信息方面,ItMARR具有关键作用。方法:ItMARR数据以汇总形式收集,根据第40/2004号法律规定,必须提交这些数据。本文的目的是对意大利执行IUI和ART的授权中心的活动进行全面概述。本文使用的数据是指2021年1月1日至12月31日期间开始的MAR治疗。结果:340个中心进行了MAR技术。2021年共进行了92407个ART周期和15660个IUI周期。配子捐赠周期占ART活动的14.6%和IUI活动的4.2%。每百万育龄妇女接受抗逆转录病毒治疗的周期为9077个。2021年,意大利总人口中3.8%的新生儿是抗逆转录病毒治疗的结果。与前一年相比,2021年MAR活动大幅增加,而前一年由于COVID-19大流行,生殖治疗受到严重限制。每次移植的妊娠率分别为:fresh技术29.4%,FER技术35.2%,FO技术26.3%,OD技术41.2%,SD技术37.9%。多胎分娩的减少趋势仍在继续。结论:ItMARR已成为生殖健康领域的一项重要资产,促进了marr信息的更好传播。ItMARR正在努力实现“逐周期”数据收集系统。这将使意大利的监测系统与其他欧洲国家保持一致。
{"title":"Medically-assisted reproduction in Italy, 2021 data from the Italian MAR Registry.","authors":"Vincenzo Vigiliano, Giulia Scaravelli, Roberta Spoletini, Lucia Speziale, Fabiola Fedele, Simone Bolli, Monica Mazzola, Anna Bertini, Roberto DE Luca","doi":"10.23736/S2724-606X.25.05799-9","DOIUrl":"https://doi.org/10.23736/S2724-606X.25.05799-9","url":null,"abstract":"<p><strong>Background: </strong>The Italian Medically Assisted Reproduction Registry (ItMARR) was established by a Decree of the Minister of Health issued on October 7<sup>th</sup>, 2005. ItMARR has a crucial role in clearly and publicly disseminating epidemiological information on MAR activities and outcomes.</p><p><strong>Methods: </strong>ItMARR data are collected in aggregate form and their submission is mandatory as stipulated by Law 40/2004. The aim of this article is to make a comprehensive overview of the activity of authorized centers that perform IUI and ART in Italy. Data used in this article refer to MAR treatments started between January 1<sup>st</sup> and December 31<sup>st</sup>, 2021.</p><p><strong>Results: </strong>MAR techniques were performed by 340 centers. In total, 92,407 ART cycles and 15,660 IUI cycles were performed in 2021. Gametes donation cycles represent 14.6% of ART activity and 4.2% of IUI. ART cycles performed per million women of childbearing age were 9077. In 2021, 3.8% of births in the general population in Italy were a result of ART application. In 2021, MAR activity had a strong increase compared to the previous year in which there were strong limitations on reproductive treatments due to the COVID-19 pandemic. Pregnancy rates per transfers were 29.4% with fresh techniques, 35.2% with FER, 26.3% with FO, 41.2% with OD and 37.9% with SD. The decreasing trend of multiple deliveries continues.</p><p><strong>Conclusions: </strong>The ItMARR has become a great asset in the reproductive health scenario promoting a better MAR information dissemination. ItMARR is working on the implementation towards a \"cycle-by-cycle\" data collection system. This will bring the Italian monitoring system in line with others European countries.</p>","PeriodicalId":18572,"journal":{"name":"Minerva obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Minerva obstetrics and gynecology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1